secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001790340-23-000046
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q2 net loss $12.2M; cash runway extended into 2025; IMM-1-104 Phase 1b enrolling
--------------------------------------------------------------------------------

- Net loss of $12.2M ($0.43 per share) vs $11.5M ($0.44 per share) in Q2 2022.
- Cash and equivalents $109.0M at June 30, 2023; expects cash runway into 2025.
- Completed $30M underwritten offering of 2.73M shares at $11.00 in April 2023.
- IMM-1-104 Phase 1a dose escalation completed with no dose-limiting toxicities; Phase 1b enrolling at 240mg or 320mg daily.
- RP2D expected early 2024; IND filing for IMM-6-415 expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/0001790340-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/imrx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001790340-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer